Vilacto Bio Inc is a biotech firm based in New York, NY, specializing in the development of innovative immunotherapy and vaccine treatments for a wide range of diseases. Their flagship product, LACTOACTIVE iTHER, is a potent nanoparticle compound that combines bovine colostrum with other substances to stimulate local antibody production and enhance the immune system's response. With a focus on pre-clinical development, Vilacto Bio aims to revolutionize the field of healthcare by providing effective and targeted therapies for conditions such as cancer, immunodeficiency disorders, osteoarthritis, psoriasis, thrombocytopenia, and vitiligo.
Utilizing their own facilities in Denmark, Vilacto Bio produces LACTOACTIVE iTHER, which harnesses the power of refined colostrum and a proven nanoparticle drug delivery system. This unique combination allows for precise targeting of affected cells, resulting in improved immune response and therapeutic outcomes. With a strong emphasis on research and development, Vilacto Bio is at the forefront of nanotherapy, offering a promising solution for patients seeking effective and innovative treatments for various diseases.
Generated from the website